Posted in | Medical Robotics

Corindus Vascular Robotics to Showcase FDA-cleared CorPath System at ACC Annual Meeting

Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its FDA-cleared CorPath System at the upcoming American College of Cardiology (ACC) annual meeting, March 29 – 31 in Washington, D.C. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes.

Corindus representatives will be onsite to conduct demos of the CorPath System and answer questions about the significant advantages in procedure precision and improvements in clinical outcomes made possible by robotics in the cath lab.

As a leader in the robotic space, Corindus has seen 300 percent growth in customer installs since spring of 2013. In late-2013, Corindus successfully installed a CorPath system at Orlando Regional Medical Center (ORMC), the first in Florida, as well as the first CorPath in a hospital within the Carolinas, and the second system in New York State. The adoption of the CorPath system continues to grow steadily and several customers now have two or more CorPath systems installed. CorPath systems are installed across the United States with several more pending within the next few months.

“The basic technique used in coronary angioplasties has remained largely the same since the first stent procedure was performed in 1986,” said David Handler, President and CEO of Corindus Vascular Robotics. “The introduction of robotic-assisted systems offers interventional cardiologists improvements in their ability to perform the procedure with enhanced precision, seated in a radiation-protected cockpit. We have found physicians to be extremely receptive to this technology due to the precision and effectiveness of stent placement – and their positive feedback is a testament to the incredible growth we’ve seen over the last year.”

Most recently, Corindus announced a partnership with Sanford Health and The Leona M. and Harry B. Helmsley Charitable Trust to launch a technical feasibility investigation for a remote robotics program. The program is intended to empower an interventional cardiologist at a major center to robotically control the movement of interventional devices at a remote facility.

“We are committed to pioneering a positive change in the delivery of heart care and making a significant impact for patients,” continued Handler.

For a demonstration of robotic angioplasty with the CorPath System, register here and visit them at ACC at booth #1343.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Corindus, Inc.. (2019, February 19). Corindus Vascular Robotics to Showcase FDA-cleared CorPath System at ACC Annual Meeting. AZoRobotics. Retrieved on March 28, 2020 from https://www.azorobotics.com/News.aspx?newsID=5469.

  • MLA

    Corindus, Inc.. "Corindus Vascular Robotics to Showcase FDA-cleared CorPath System at ACC Annual Meeting". AZoRobotics. 28 March 2020. <https://www.azorobotics.com/News.aspx?newsID=5469>.

  • Chicago

    Corindus, Inc.. "Corindus Vascular Robotics to Showcase FDA-cleared CorPath System at ACC Annual Meeting". AZoRobotics. https://www.azorobotics.com/News.aspx?newsID=5469. (accessed March 28, 2020).

  • Harvard

    Corindus, Inc.. 2019. Corindus Vascular Robotics to Showcase FDA-cleared CorPath System at ACC Annual Meeting. AZoRobotics, viewed 28 March 2020, https://www.azorobotics.com/News.aspx?newsID=5469.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit